MA30221B1 - Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments - Google Patents
Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicamentsInfo
- Publication number
- MA30221B1 MA30221B1 MA31180A MA31180A MA30221B1 MA 30221 B1 MA30221 B1 MA 30221B1 MA 31180 A MA31180 A MA 31180A MA 31180 A MA31180 A MA 31180A MA 30221 B1 MA30221 B1 MA 30221B1
- Authority
- MA
- Morocco
- Prior art keywords
- azacyclyl
- medicaments
- preparation
- substituted
- aryldihydroisoquinolinones
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des aryldihydro-isoquinoléinones substituées par un azacyclyle et leurs dérivés, et leurs sels physiologiquement tolérés et dérivés physiologiquement fonctionnels, leur préparation, des médicaments comprenant au moins une aryldihydro-isoquinoléinone substituée par un azacyclyle de l'invention ou son dérivé, et l'utilisation des aryldihydro-isoquinoléinones substituées par un azacyclyle de l'invention et leurs dérivés en tant qu'antagonistes de MCH.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006007045 | 2006-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30221B1 true MA30221B1 (fr) | 2009-02-02 |
Family
ID=38191074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31180A MA30221B1 (fr) | 2006-02-15 | 2008-08-15 | Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments |
Country Status (21)
Country | Link |
---|---|
US (1) | US8822495B2 (fr) |
EP (1) | EP1987020B1 (fr) |
JP (1) | JP5175228B2 (fr) |
KR (1) | KR20080095877A (fr) |
CN (1) | CN101384583A (fr) |
AR (1) | AR059458A1 (fr) |
AU (1) | AU2007214709A1 (fr) |
BR (1) | BRPI0707872A2 (fr) |
CA (1) | CA2636873A1 (fr) |
CR (1) | CR10160A (fr) |
EC (1) | ECSP088680A (fr) |
IL (1) | IL193340A0 (fr) |
MA (1) | MA30221B1 (fr) |
NI (1) | NI200800217A (fr) |
NZ (1) | NZ570503A (fr) |
RU (1) | RU2008136898A (fr) |
TN (1) | TNSN08326A1 (fr) |
TW (1) | TW200800908A (fr) |
UY (1) | UY30166A1 (fr) |
WO (1) | WO2007093364A1 (fr) |
ZA (1) | ZA200805939B (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5072602B2 (ja) | 2004-12-17 | 2012-11-14 | イーライ リリー アンド カンパニー | Mch受容体アンタゴニストとしてのチアゾロピリジノン誘導体 |
US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
CN101460503A (zh) * | 2006-06-08 | 2009-06-17 | 伊莱利利公司 | 新的mch受体拮抗剂 |
WO2007146758A2 (fr) * | 2006-06-08 | 2007-12-21 | Eli Lilly And Company | Nouveaux antagonistes de récepteur de mch |
BRPI0806371A2 (pt) | 2007-01-22 | 2011-09-13 | Gtx Inc | agentes ligação de receptor nuclear |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US8853392B2 (en) | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
JP5665540B2 (ja) | 2007-09-11 | 2015-02-04 | アッヴィ・インコーポレイテッド | オクタヒドロ−ピロロ[3,4−b]ピロールn−オキシド |
AR068745A1 (es) * | 2007-10-08 | 2009-12-02 | Panacea Biotec Ltd | Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos |
CA2702467C (fr) * | 2007-10-17 | 2012-11-27 | Sanofi-Aventis | Carboxamides de n-phenyl-bipyrrolidine substitues et leur utilisation therapeutique |
AU2008312636B2 (en) * | 2007-10-17 | 2013-03-14 | Sanofi-Aventis | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine H3 receptor modulators |
US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
JP2012503595A (ja) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
AR074466A1 (es) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
WO2010147234A1 (fr) * | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Dérivé de diarylamide-spirodiamine |
KR101116234B1 (ko) | 2009-10-29 | 2014-03-06 | (주)퓨쳐켐 | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
AR081908A1 (es) * | 2010-05-11 | 2012-10-31 | Sanofi Aventis | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas |
JP5784110B2 (ja) | 2010-05-11 | 2015-09-24 | サノフイ | 置換されたn−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用 |
TW201206889A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
WO2011143161A1 (fr) | 2010-05-11 | 2011-11-17 | Sanofi | Dérivés de n-hétérocycloalkyl-bipyrrolidinylphénylamide substitués, préparation et utilisation thérapeutique de ceux-ci |
WO2011143162A1 (fr) | 2010-05-11 | 2011-11-17 | Sanofi | Carboxamides de n-hétéroaryl-bipyrrolidine substitués, leur préparation et leur utilisation thérapeutique |
EP2569280B1 (fr) | 2010-05-11 | 2015-02-25 | Sanofi | Phényl-cycloalkyl-pyrrolidine- (pipéridine-) spirolactames et amides substituées, leur préparation et utilisation thérapeutique |
EP2585462B1 (fr) * | 2010-06-24 | 2020-02-26 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes) |
US9134238B2 (en) * | 2010-12-01 | 2015-09-15 | Nalco Company | Method for determination of system parameters for reducing crude unit corrosion |
TWI570122B (zh) * | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
CN103086894B (zh) * | 2013-02-25 | 2014-10-01 | 武汉迪可表面技术有限公司 | 一种电镀添加剂3-甲基-3-氨基丁炔的合成方法 |
RU2708690C2 (ru) | 2013-08-08 | 2019-12-11 | Галапагос Нв | Производные тиено[2,3-c]пиранов в качестве cftr модуляторов |
CA3093189A1 (fr) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification et utilisation d'inhibiteurs d'erk5 |
US20210380521A1 (en) * | 2018-10-11 | 2021-12-09 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
DK0590455T3 (da) * | 1992-09-28 | 2001-01-22 | Hoechst Ag | Antiarrytmiske og cardioprotektive substiuerede 1(2H)-isoquinoliner, fremgangsmåde til deres fremstilling, lægemiddel indeh |
GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
JP2005519876A (ja) * | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | 2−アミノキノリン化合物 |
DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US20060111357A1 (en) * | 2002-12-11 | 2006-05-25 | Frimurer Thomas M | Quinoline compounds for use in mch receptor related disorders |
JP2006522812A (ja) * | 2003-04-11 | 2006-10-05 | スミスクライン ビーチャム コーポレーション | 複素環mchr1アンタゴニスト |
BRPI0415667A (pt) * | 2003-10-23 | 2006-12-19 | Glaxo Group Ltd | composto, método para tratar obesidade, diabete, depressão ou ansiedade em um mamìfero, processo para preparar um composto, e, uso de um composto |
US20050256124A1 (en) * | 2004-04-15 | 2005-11-17 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
-
2007
- 2007-02-13 CA CA002636873A patent/CA2636873A1/fr not_active Abandoned
- 2007-02-13 NZ NZ570503A patent/NZ570503A/en unknown
- 2007-02-13 CN CNA2007800057794A patent/CN101384583A/zh active Pending
- 2007-02-13 KR KR1020087019922A patent/KR20080095877A/ko not_active Application Discontinuation
- 2007-02-13 TW TW096105359A patent/TW200800908A/zh unknown
- 2007-02-13 JP JP2008554653A patent/JP5175228B2/ja not_active Expired - Fee Related
- 2007-02-13 BR BRPI0707872-2A patent/BRPI0707872A2/pt not_active IP Right Cessation
- 2007-02-13 AU AU2007214709A patent/AU2007214709A1/en not_active Abandoned
- 2007-02-13 RU RU2008136898/04A patent/RU2008136898A/ru not_active Application Discontinuation
- 2007-02-13 WO PCT/EP2007/001212 patent/WO2007093364A1/fr active Application Filing
- 2007-02-13 EP EP07711518A patent/EP1987020B1/fr active Active
- 2007-02-15 UY UY30166A patent/UY30166A1/es not_active Application Discontinuation
- 2007-02-15 AR ARP070100658A patent/AR059458A1/es not_active Application Discontinuation
-
2008
- 2008-07-08 ZA ZA200805939A patent/ZA200805939B/xx unknown
- 2008-07-17 CR CR10160A patent/CR10160A/es not_active Application Discontinuation
- 2008-08-10 IL IL193340A patent/IL193340A0/en unknown
- 2008-08-11 TN TNP2008000326A patent/TNSN08326A1/en unknown
- 2008-08-13 EC EC2008008680A patent/ECSP088680A/es unknown
- 2008-08-14 NI NI200800217A patent/NI200800217A/es unknown
- 2008-08-14 US US12/191,662 patent/US8822495B2/en not_active Expired - Fee Related
- 2008-08-15 MA MA31180A patent/MA30221B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
RU2008136898A (ru) | 2010-03-20 |
TW200800908A (en) | 2008-01-01 |
UY30166A1 (es) | 2007-09-28 |
US20090264403A1 (en) | 2009-10-22 |
BRPI0707872A2 (pt) | 2011-05-10 |
IL193340A0 (en) | 2009-05-04 |
JP2009526793A (ja) | 2009-07-23 |
TNSN08326A1 (en) | 2009-12-29 |
AR059458A1 (es) | 2008-04-09 |
ZA200805939B (en) | 2009-12-30 |
CN101384583A (zh) | 2009-03-11 |
CR10160A (es) | 2008-10-06 |
NZ570503A (en) | 2010-07-30 |
JP5175228B2 (ja) | 2013-04-03 |
KR20080095877A (ko) | 2008-10-29 |
WO2007093364A1 (fr) | 2007-08-23 |
AU2007214709A1 (en) | 2007-08-23 |
NI200800217A (es) | 2010-02-10 |
CA2636873A1 (fr) | 2007-08-23 |
EP1987020A1 (fr) | 2008-11-05 |
US8822495B2 (en) | 2014-09-02 |
EP1987020B1 (fr) | 2012-10-03 |
ECSP088680A (es) | 2008-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30221B1 (fr) | Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments | |
MA30765B1 (fr) | Derives innovants du thiophene | |
MA30722B1 (fr) | Utilisation de derives de l'adenosine en tant qu'agonistes du recepteurs a2a | |
MA34469B1 (fr) | Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci | |
MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
MA31849B1 (fr) | Nouveaux dérivés de pyrimidine | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
MA30226B1 (fr) | Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique. | |
MA31021B1 (fr) | Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase | |
MA31898B1 (fr) | Compositions pharmaceutiques | |
MA30208B1 (fr) | Derives de pyrimidine utilises en tant qu'inhibiteurs de kinase pi -3 | |
BRPI0511874A (pt) | derivados da pirrolopiridina | |
EA200870423A1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
TN2010000130A1 (fr) | Derives de quinazolinedione, leur preparation et leurs applications therapeutiques | |
MA33679B1 (fr) | Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole | |
ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
TW200801022A (en) | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |